Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
What to look forward to in GaBI Journal, 2017, Issue 2 / Professor Philip D Walson, MD, USA/Germany
Trends and challenges in biosimilars pricing and reimbursement policies in Europe and beyond / Alessandro Curto, MSSc, Italy
Strategies for pricing of pharmaceuticals and generics in developing countries / Brian Godman, BSc, PhD; Professor Mohamed Azmi Hassali, PhD
Patent expiry and costs for anticancer medicines for clinical use / Brian Godman, BSc, PhD; Claudia Wild, PhD; Alan Haycox, PhD
Current overview of biosimilars in Iran / Hamideh Aghajani-Lazarjani, PhD; Fereidoun Mahboudi, PhD, Iran
Assessing the perception and awareness of Maltese clinicians on biosimilars: where are we? / Louise Grech,PhD; Kathlene Cassar M.Sc; David Zammit Dimech, MD; Dustin Balzan, B.Pharm (Hons); Anthony Cutajar M.Sc; Paul John Cassar, MD, Malta
Pharmacy-mediated substitution of biosimilars: a global perspective / HC Larkin; JC Macdonald; RS Lumsden, PhD
A survey of Australian prescribers’ views on the naming and substitution of biologicals / Stephen P Murby, FRSA; Michael S Reilly, Esq
What pricing and reimbursement policies to use for off-patent biologicals in Europe? – Results from the second EBE biological medicines policy survey / Jean-Baptiste Reiland, MSc; Barbara Freischem; Alexander Roediger, MA
Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey / Sabine Vogler, PhD; Peter Schneider, MA
Bioequivalence study of two formulations of 60 mg daclatasivir in healthy volunteers / Sattam Turky AlGhodyyr, MSc; Mohammad Khalil Mohammad, RPh., PhD; Sanabel Omar Dawabsheh; Mohammad Ali Abu Fara, MD; Majdi Naser Abu Al hajj; Rabab Fayyez Tayyem, PhD
Assessment of medicine quality in emerging markets: the changing face of inferior medicines over time / Roger Bate, USA; Lorraine Mooney, UK
The assessment of biosimilarity with SABE and IBE criteria under a switching/alternating design / Aijing Zhang, PhD; Associate Professor Jung-Ying Tzeng; Professor Shein-Chung Chow, PhD, USA (Biosimilarity and Interchangeability)
Real world data about biosimilars: results from an Italian distributed network / Gianluca Trifirò; Ylenia Ingrasciotta; Ilaria Marcianò; Armando Genazzani
Generic immonusuppressants comparability studies / Marc Maliepaard, PhD; Professor Hubert G M Leufkens, PharmD, PhD, The Netherlands (Generic Immunosuppressants in Transplantation)
Generic immunosuppression in transplantation: a controversial analysis / Jacques Rottembourg, MD
Pharmacovigilance, traceability and building trust in biosimilar medicines / Professor Teun van Gelder, MD, PhD; Benedicte Lunddahl, DVM; ProfessorBarbara OM Claus, PharmD, PhD
Biosimilars in Germany: Guidance of the Drug Commission of the German Medical Association / Professor Wolf-Dieter Ludwig, PhD; Stanislava Dicheva, PhD, Germany
Physicians associations comment on FDA’s interchangeability guidance / Michelle Derbyshire, PhD, GaBI Online Editor
Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and USA / Subramanian Venkatesan, MSc; Martine Lamfers, PhD; Professor Sieger Leenstra, MD, PhD; Arnold G. Vulto, PharmD, PhD, FCP
Interchangeability of biosimilars in the US and around the world / Michelle Derbyshire, PhD, GaBI Online Editor
Abstracted Scientific Content
Generic prices estimated for four novel cancer drugs / Eleanor Bird, GaBI Journal Editor
Effective generics substitution / Maysoon Delahunty, GaBI Journal Editor
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.